Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

Ann Rheum Dis. 2007 Jan;66(1):133-4. doi: 10.1136/ard.2006.057745.

Authors

M K de Vries, G J Wolbink, S O Stapel, E R de Groot, B A C Dijkmans, L A Aarden, I E van der Horst-Bruinsma

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal / blood
Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use*
Antibody Formation
Antirheumatic Agents / blood
Antirheumatic Agents / immunology
Antirheumatic Agents / therapeutic use*
Humans
Infliximab
Male
Middle Aged
Spondylitis, Ankylosing / drug therapy*
Spondylitis, Ankylosing / immunology
Treatment Failure
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Infliximab